Brain Tumor Imaging by Positron Emission Computed Tomography Using 11C-Labeled Amino Acids

Hübner, Karl; Purvis, J. T.; Mahaley, S. M.; Robertson, James T.; Rogers, Shannon M.; Gibbs, W.D.; King, Paul H.; Partain, C. Leon

doi:10.1097/00004728-198206000-00020

Cited by 66 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brain tumors, it has given rise in the past to quite a few approaches (1,2). Several studies have already showed data on oxydative, glycolytic or amino-acid metabolism in glioma patients (3,4).…”

Section: Introductionmentioning

confidence: 99%

Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine

et al. 1986

View full text Add to dashboard Cite

Brain protein synthesis may be evaluated in vivo by a PET three compartment methionine model. 14 human brain tumor patients were studied. Protein synthesis rate (PSR) was increased in any glial tumor even in low grades, but this increase was statistically more important in anaplastic tumor. Radiotherapy action was evaluated in two patients. Local tumoral PSR was reduced to normal brain PSR after treatment. No difference was seen in normal cortex contralateral to the lesion between pre and post radiotherapy examination. 11 C-L-Methionine incorporation measured by PET looks as a very sensitive method for studying tumor metabolism and treatment effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Shortly after the introduction of brain imaging with radiolabeled AA [12], the first reports already indicated its potential benefit in diagnostic accuracy, as well as tumor extent of glioma compared to CT [13] or MRI [14]. In contrast to FDG, especially FET shows significantly lower uptake in non-neoplastic inflammatory cells [15].…”

Section: Amino Acid Tracersmentioning

confidence: 99%

“…Whereas the use of MET is limited to centers with an on-site cyclotron due to the short half-life (20 min) of carbon-11 [12], the possibility to radiolabel FET with fluorine-18 (physical half-life 110 min) [19,20] helped to distribute metabolic brain tumor imaging to smaller centers without on-site cyclotron. Despite the development of amino acid tracers with longer half-lives, molecular imaging in neurooncology is still far more limited than oncologic PET scans using 18 F-FDG for non-CNS malignancies [21].…”

Section: Amino Acid Tracersmentioning

confidence: 99%

PET/MRI and brain tumors: focus on radiation oncology treatment planning

Oehlke

Grosu

2016

Clin Transl Imaging

View full text Add to dashboard Cite

In brain tumors, imaging by magnetic resonance imaging (MRI) can very accurately visualize anatomy and morphology of healthy and malignant tissue, but neither contrast-enhancing areas in T1-weighted sequences, nor hyperintensities in T2/FLAIR sequences are specific for tumor tissue, especially when considering the manifold alterations resulting from previous treatment. Imaging the biology of tumor tissue by positron emission tomography (PET), therefore, is a highly interesting approach to improve the detection of macroscopic tumor which is the prerequisite for high-precision radiotherapy treatment planning. This review will focus on the benefits of amino acid tracers (L-[methyl-11 C]methionine (MET) and O-(2-[ 18 F]fluoroethyl)-L-tyrosine (FET)) in neurooncology and their implementation in radiation oncology. Furthermore, a brief overview of the current impact of 2-deoxy-2-(18F)fluoro-D-glucose (FDG), nucleic acid analogs, hypoxia tracers, and Somatostatin receptor (SSTR) analogs on radiotherapy planning in brain tumors is provided. Among advances in multiparametric MRI, Diffusionweighted imaging (DWI) has attracted particular attention since it can predict prognosis, as well as indicate response to treatment and has already been introduced into target volume definition for radiotherapy of various cancers (e.g., prostate and rectal cancer). Additionally, advances in MR spectroscopy (MRS) are mentioned. Finally, these findings will be discussed concerning their influence on current aspects of integrated PET/MR hybrid imaging.

show abstract

“…Amino acids such as 11 C-methionine ( Fig. 9) are especially appropriate to help in the differential diagnosis of malignant brain tumours and in follow up studies [73]. Radiopharmaceuticals with an affinity to the neurotransmitter system have been applied in neurological and psychiatric research, e.g.…”

Section: Neurological Petmentioning

confidence: 99%

In vivo functional imaging with SPECT and PET

Herzog

2001

Radiochimica Acta

View full text Add to dashboard Cite

Single photon emission computed tomography / Positron emission tomography / Functional imaging / Radiopharmaceuticals / Gamma cameraSummary. Nuclear medicine methods permit the visualisation of a variety of metabolic and physiological processes all over the body. Although planar scintigraphy has been found useful for many questions, detailed spatial information about the diseased organ can only be obtained with tomographic methods. Dependent on the radionuclide involved, two different tomographic procedures are available: single photon emission computed tomography (SPECT) and positron emission tomography (PET). The first part of this paper describes shortly the historical development of these methods as well as their technical and methodological basics. To elucidate the large variety of possible applications, an overview of SPECT and PET procedures utilised in research as well as in clinical practice are presented. Furthermore, both methods are compared and their individual advantages are pointed out.

show abstract

Brain Tumor Imaging by Positron Emission Computed Tomography Using 11C-Labeled Amino Acids

Cited by 66 publications

References 0 publications

Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine

Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine

PET/MRI and brain tumors: focus on radiation oncology treatment planning

In vivo functional imaging with SPECT and PET

Contact Info

Product

Resources

About